Webinars & Online Seminars

What will be covered?

• How PathHunter services save development time compared to in-house assays
• Screening and profiling biologics with highly specific and sensitive assays that produce robust and reproducible results
• Example data from marketed drugs, like Pembrolizumab and Nivolumab, using these cell-based assays

What will be covered?

• RTK biology and drug discovery importance
• Tools needed to create your own RTK cell lines and assays
• Experimental design and workflows
• Applications of RTK and related cell-based assays

What will be covered?

• 世界で唯一：プライマリー細胞を使用した、ガンの微小細胞環境モデル
• 話題となっている免疫チェックポイント阻害剤の評価例
• 医療抗体の中でも低分子化合物が活躍？
• BioMAPシステムの応用例

What will be covered?

• Eliminating donor variability in cytotoxicity assays with single donor-derived primary human KILR CD16 Effector Cells
• Better analysis of antibody’s cytotoxicity profile with better Hill Slopes and higher S:B compared to PBMCs
• Faster assessment of redirected T cell-mediated cytotoxicity with rapid killing kinetics of the CD16 Effector cells

What will be covered?

• Overview of compound-target engagement
• Tools and workflow to create your own cell-based target engagement assay
• Applications of InCELL Pulse assays

What will be covered?

• Using phenotypic profiling to characterize clinically successful drugs for a given indication
• Combining target-based and phenotypic data to prioritize drugs for repurposing
• Understanding how multi-targeted kinases can be pivoted towards new indications

What will be covered?

• Role of GPCRs in human cardiovascular system
• Strategies for exploiting orphan GPCRs recently paired with endogenous ligands illustrated by Apelin and Elabela/Toddler
• Identifying biased agonists using pharmacologically-relevant functional cell based assays
• Validating assays and minimizing inter-assay variation

What will be covered?

• Overview of compound-target engagement and InCELL Pulse platform
• Kinase drug discovery importance
• Tools and workflow needed to create your own target engagement assay
• Validation data showing several examples of diverse kinases

What will be covered?

• 抗腫瘍免疫応答が増強に活用される免疫チェックポイント阻害剤の評価系
• PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, VISTA などの実施例
• 放射性同位体を使用しないADCC（抗体依存性細胞傷害）の評価系

What will be covered?

• Overview of the mu opioid receptor signaling
• GPCR splicing, using OPRM1 as an example
• Region and cell specific splicing
• Functional consequences of 5’ splicing
• Functional consequences of 3’ splicing

What will be covered?

• Overview of compound-target engagement
• Tools needed to create your own target engagement assay
• Experimental design and workflow
• Applications of InCELL Pulse assays

What will be covered?

• Screening approaches for GPCR drug discovery
• Creating a duplexed assay to monitor calcium and β-arrestin in a single well

• Determine potential bias for various drugs and define potency ranking

What will be covered?

• Challenges in immuno-oncology drug development
• Tools to expedite and simplify any immuno-oncology drug development pipeline

What will be covered?

• Overview of the BioMAP® immuno-oncology/oncology systems
• Information BioMAP iOnc studies provide
• Host stromal/vascular - tumor microenvironment biology
• Case studies of profiling Ab therapies (anti-PD-1, anti-CTLA-4, etc.) and preclinical compounds

What will be covered?

• Overview of the BioMAP Diversity PLUS phenotypic screening platform's modeling of broad human tissue and disease biology
• Details of how Diversity PLUS profiling guides new indications for marketed drugs and pre-clinical candidates
• Examples highlighting how this technology is used to support repositioning of approved drugs for alternate indications

What will be covered?

• Creation of cell-based bioassays for potency and stability testing
• Application, development and validation of assays with drug molecule
• Case studies on Avastin (bevacizumab), Eylea (aflibercept) and Lucentis (ranibizumab)
• Qualified assays for > 30 biosimilars